blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1871752

EP1871752 - AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  23.07.2010
Database last updated on 31.08.2024
Most recent event   Tooltip23.07.2010Application deemed to be withdrawnpublished on 25.08.2010  [2010/34]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
[2010/10]
Former [2008/01]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
Inventor(s)01 / COLEMAN, Paul, J.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
02 / SCHREIER, John
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
 [2008/01]
Representative(s)Buchan, Gavin MacNicol, et al
Merck Sharp & Dohme Limited
European Patent Department
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU / GB
[N/P]
Former [2008/01]Buchan, Gavin MacNicol, et al
Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
Application number, filing date06740787.410.04.2006
[2008/01]
WO2006US13253
Priority number, dateUS20050670542P12.04.2005         Original published format: US 670542 P
US20050718340P19.09.2005         Original published format: US 718340 P
[2008/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006110626
Date:19.10.2006
Language:EN
[2006/42]
Type: A1 Application with search report 
No.:EP1871752
Date:02.01.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 19.10.2006 takes the place of the publication of the European patent application.
[2008/01]
Search report(s)International search report - published on:US19.10.2006
(Supplementary) European search report - dispatched on:EP27.08.2009
ClassificationIPC:C07D277/56, C07C233/69, C07C235/42, C07C237/38, C07D231/12, C07D231/14, C07D249/06, A61K31/426, A61P25/20
[2009/40]
CPC:
C07C237/38 (EP,US); A61P1/04 (EP); A61P1/08 (EP);
A61P11/06 (EP); A61P13/02 (EP); A61P13/08 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P15/10 (EP);
A61P19/10 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/06 (EP); A61P25/08 (EP); A61P25/14 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P25/30 (EP); A61P3/04 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P5/38 (EP); A61P9/00 (EP); A61P9/02 (EP);
A61P9/04 (EP); A61P9/10 (EP); A61P9/12 (EP);
C07C233/69 (EP,US); C07C235/42 (EP,US); C07D207/337 (EP,US);
C07D231/12 (EP,US); C07D231/14 (EP,US); C07D233/54 (EP,US);
C07D249/06 (EP,US); C07D249/08 (EP,US); C07D257/04 (EP,US);
C07D261/18 (EP,US); C07D263/34 (EP,US); C07D277/56 (EP,US);
C07D285/06 (EP,US); C07D333/24 (EP,US); C07D333/60 (EP,US);
C07D417/04 (EP,US); C07C2601/02 (EP,US) (-)
Former IPC [2008/01]C07D277/56
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/01]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:ANTAGONISTEN DES AMIDOPROPOXYPHENYLOREXINREZEPTORS[2008/01]
English:AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS[2008/01]
French:ANTAGONISTES DU RÉCEPTEUR DE L' OREXINE DE TYPE AMIDOPROPOXYPHÉNYLE[2008/01]
Entry into regional phase12.11.2007National basic fee paid 
12.11.2007Search fee paid 
12.11.2007Designation fee(s) paid 
12.11.2007Examination fee paid 
Examination procedure11.10.2007Amendment by applicant (claims and/or description)
12.11.2007Examination requested  [2008/01]
22.10.2009Despatch of a communication from the examining division (Time limit: M04)
03.03.2010Application deemed to be withdrawn, date of legal effect  [2010/34]
08.04.2010Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2010/34]
Fees paidRenewal fee
18.03.2008Renewal fee patent year 03
16.04.2009Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.04.201005   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E]EP1716851  (ISHIHARA SANGYO KAISHA [JP]) [E] 1-3,13,15,17,19,22 * page 18, line 9 * * page 19, line 39 * * page 22, line 19 - line 22 * * page 22, line 26 - line 27 * * page 23, line 46 - page 24, line 6 * * page 24, line 50 * * paragraph [0043] *;
 [X]US5356865  (MUELLER KLAUS-HELMUT [DE], et al) [X] 1,2,13,19,20 * examples 108-111,170 *;
 [X]US4649146  (TAKAYA TAKAO [JP], et al) [X] 1,3,6,13,15,17,22 * example 94 *;
 [X]US3228950  (RENK ERNST F, et al) [X] 1-3,13,15,17,19 * column 6, line 43 - line 44 *;
 [X]US4309433  (HIRAI KENTARO, et al) [X] 1,3,10,13,15,17,22 * claims 3-6 *;
 [X]  - MALAN S F ET AL, "Fluorescent ligands for the histamine H2 receptor: synthesis and preliminary characterization", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, (20041215), vol. 12, no. 24, ISSN 0968-0896, pages 6495 - 6503, XP004646490 [X] 1,3,4,10,13,15,17,22 * compound 12 *

DOI:   http://dx.doi.org/10.1016/j.bmc.2004.09.018
International search[A]US4826990  (MUSSER JOHN H [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.